For example, patients whose tumours show high TUBB3 or high MDR1 might be initially triaged away from docetaxel to an alternative (maybe to an epothilone or a platinum, etc.), or an added agent might be administered to counteract the specific resistance (e.g., a P-gp inhibitor in a clinical trial context or a PI3K inhibitor for a PIK3CA-mutant, Akt-activated tumour). This evidence concerns the gene PIK3CA and neoplasm.